Email is the best mode of contact due to very high call volumes

Phone: 905-844-5677


The Bone Research and Education Centre (BREC) established in 2014 is a centre of excellence in rare metabolic bone diseases. The BREC is able to conduct phase 1 to 4 clinical research trials and is equipped with state-of-the-art monitoring facilities including cardiac monitors, EKGs as well as on-site imaging and lab facilities. The nursing staff are ICU trained and experienced and the facility can accommodate research studies requiring inpatient care.

The following studies are currently being conducted at the BREC:

1. PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism


2. A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men with Osteoporosis


3. SHP634-404 An open label study investigating the Safety and Efficacy of rhPTH-1-84 in subjects with hypoparathyroidism


4. SHP634-401 Study of the Effect of Recombinant Human Parathyroid Hormone [rhPTH(1-84)] on Symptoms Improvement and Metabolic Control Among Adults With Hypoparathyroidism


5. Efficacy of low dose Denosumab in maintaining bone mineral density in postmenopausal women with osteoporosis: a real world, prospective observational study


6. (PARADIGM) Physicians Advancing Disease Knowledge in Hypoparathyroidism): A natural history registry for patients with chronic hypoparathyroidism


7. Canadian National Hypoparathyroidism Registry- Observational prospective study of hypoparathyroidism


8. Osteoporosis Treatment Rate Following Hip Fracture in a Community Hospital: A retrospective chart review 


9. Canadian Registry for Atypical Femur Fractures


10. Hypophosphatasia (HPP)


11.  X-linked Hypophosphatemia Disease Monitoring Program – (XLH-DMP)


12. CALIBRATE: A Phase 3 Open-Label Study Evaluating the Efficacy and Safety of EncaleretCompared to Standard of Care in Adolescent and Adult Participants withAutosomal Dominant Hypocalcemia Type 1 (ADH1)




14. PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel Group Trial, with an Open-Label Extension,Investigating the Safety, Tolerability and Efficacy of TransCon PTHAdministered Subcutaneously Daily in Adults with Hypoparathyroidism